Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate drug-drug interactions between cannabis extracts containing
Tetrahydrocannabinol (THC) and THC+ Cannabinoids (CBD) and probe drugs for select CYP450
pathways including: caffeine (CYP1A2), omeprazole (CYP2C19), losartan (CYP2C9),
dextromethorphan (CYP2D6), and midazolam (CYP3A).
Phase:
Phase 1
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
National Center for Complementary and Integrative Health (NCCIH) Washington State University